Some evidence instead suggests that the appearance of WMH precedes tau-mediated neurodegeneration in the AD disease trajectory [28, 35, 37], and changes in white matter and blood–brain barrier integrity have been reported at preclinical disease stages in patients with both sporadic and autosomal-dominant AD [38, 39]. The gene discussed is MAPT; the disease is Alzheimer disease.